Patents by Inventor David J. Shapiro

David J. Shapiro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12180159
    Abstract: A set of small molecules ER? biomodulators that kill therapy-resistant ER? positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: December 31, 2024
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: David J. Shapiro, Paul J. Hergenrother, Matthew W. Boudreau
  • Patent number: 11584718
    Abstract: A set of small molecules ER? biomodulators that kill therapy-resistant ER? positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: February 21, 2023
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: David J. Shapiro, Paul J. Hergenrother, Matthew W. Boudreau
  • Publication number: 20210340100
    Abstract: A set of small molecules ER? biomodulators that kill therapy-resistant ER? positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.
    Type: Application
    Filed: May 13, 2021
    Publication date: November 4, 2021
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: David J. SHAPIRO, Paul J. HERGENROTHER, Matthew W. BOUDREAU
  • Publication number: 20210276951
    Abstract: A set of small molecules ER? biomodulators that kill therapy-resistant ER? positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.
    Type: Application
    Filed: July 1, 2019
    Publication date: September 9, 2021
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: David J. SHAPIRO, Paul J. HERGENROTHER, Matthew W. BOUDREAU
  • Patent number: 11046647
    Abstract: A set of small molecules ER? biomodulators that kill therapy-resistant ER? positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: June 29, 2021
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: David J. Shapiro, Paul J. Hergenrother, Matthew W. Boudreau
  • Publication number: 20200190029
    Abstract: A set of small molecules ER? biomodulators that kill therapy-resistant ER? positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.
    Type: Application
    Filed: February 26, 2020
    Publication date: June 18, 2020
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: David J. SHAPIRO, Paul J. Hergenrother, Matthew W. Boudreau
  • Patent number: 8871751
    Abstract: The disclosure herein relates to nuclear hormone receptors including steroid hormone receptors, for example in connection with estrogen, progesterone, and androgen. Embodiments of compositions and methods are disclosed including such relating to compounds, including substituted theophyllines, capable of functioning as inhibitors of estrogen receptor alpha-mediated gene expression and having the ability to modify cancer cells and treat cancer, including breast cancers and resistant breast cancers, particularly those that are resistant to tamoxifen. In embodiments, methods of inhibiting breast cancer cells and resistant breast cancer cells are provided. In embodiments, a useful inhibitor compound includes TPSF/NSC 97998 and other compounds.
    Type: Grant
    Filed: January 19, 2009
    Date of Patent: October 28, 2014
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: David J. Shapiro, Chengjian Mao, Milu Tresa Cherian, Nicole M. Patterson
  • Publication number: 20090291972
    Abstract: The disclosure herein relates to nuclear hormone receptors including steroid hormone receptors, for example in connection with estrogen, progesterone, and androgen. Embodiments of compositions and methods are disclosed including such relating to compounds, including substituted theophyllines, capable of functioning as inhibitors of estrogen receptor alpha-mediated gene expression and having the ability to modify cancer cells and treat cancer, including breast cancers and resistant breast cancers, particularly those that are resistant to tamoxifen. In embodiments, methods of inhibiting breast cancer cells and resistant breast cancer cells are provided. In embodiments, a useful inhibitor compound includes TPSF/NSC 97998 and other compounds.
    Type: Application
    Filed: January 19, 2009
    Publication date: November 26, 2009
    Inventors: David J. SHAPIRO, Chengjian Mao, Milu Tresa Cherian, Nicole M. Patterson
  • Patent number: 7153685
    Abstract: Novel tamoxifen inducible and ICI 182,780 repressible expression systems comprising mutant estrogen receptors and mutant estrogen response element are disclosed. Such systems have a wide variety of applications, including gene therapy and in vivo and in vitro expression, as well as their use in transgenic animals.
    Type: Grant
    Filed: March 11, 2002
    Date of Patent: December 26, 2006
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Chengjian Mao, David J. Shapiro
  • Publication number: 20030199022
    Abstract: Novel tamoxifen inducible and ICI 182,780 repressible expression systems comprising mutant estrogen receptors and mutant estrogen response element are disclosed. Such systems have a wide variety of applications, including gene therapy and in vivo and in vitro expression, as well as their use in transgenic animals.
    Type: Application
    Filed: March 11, 2002
    Publication date: October 23, 2003
    Applicant: Board of Trustees of University of Illinois
    Inventors: Chengjian Mao, David J. Shapiro